Acute Effects of Cannabis on Cognition and Affect
NCT07296874, Phase 1, Recruiting, Washington State University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Acute Effects of Cannabis on Cognition and Affect | ClinicalTrials.gov |
| NCT number | NCT07296874 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Phase 1 | ClinicalTrials.gov |
| Enrollment | 92 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Washington State University | ClinicalTrials.gov |
| Conditions | Cannabis Use | ClinicalTrials.gov |
| Interventions | THC 20mg, Placebo | ClinicalTrials.gov |
| First posted | 2025-12-22 | ClinicalTrials.gov |
| Last updated | 2026-10-29 | ClinicalTrials.gov |
Registered outcomes 63
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Event-Based Prospective Memory - Number of Difficulty Ratings Provided | This outcome will be assessed during both sessions, within 90 minutes post-treatment. | Event-based prospective memory will be assessed using a difficulty ratings task. At the beginning of the session, participants will be asked to try to remember to rate how difficult they found each test immediately after it is completed, using a 0 (not at all difficult) to 10 (extremely difficult) scale. The primary outcome of interest is the number (or percentage) of difficulty ratings they remember to provide. | ClinicalTrials.gov |
| Primary | Time-Based Prospective Memory - Token Task | This outcome will be assessed during both sessions, within 90 minutes post-treatment. | Time-based prospective memory will be assessed using a token task. Participants will be instructed to try to remember to request a token every 10 minutes. A clock will be positioned face down on the table for them to refer to the time, and we will record their clock-checking behavior. The primary outcome is the number (or percentage) of times they remember to request the token, out of the total time of the cognitive assessment session. | ClinicalTrials.gov |
| Primary | Working Memory Updating - N-Back Test Accuracy | This outcome will be assessed during both sessions, within 90 minutes post-treatment. | Cognitive flexibility and working memory updating will be assessed using the N-back test. Participants are shown strings of letters one at a time and are instructed to indicate whenever a letter appears that matches the letter shown two trials earlier. The primary outcome of interest is the percentage of correct responses made (i.e., the number of times they correctly recognize that the current letter matches the one from two trials before, etc.). | ClinicalTrials.gov |
| Primary | Verbal Working Memory - Digit Span Backwards | This outcome will be assessed during both sessions, within 90 minutes post-treatment. | Verbal working memory will be assessed using the Backwards portion of the Digit Span Test. For this test, participants are read lists of digits (of increasing lengths) and are asked to recall them in reverse order. The primary outcome of interest is the total number of correct trials. | ClinicalTrials.gov |
| Primary | Planning - Tower Test Total Achievement Score | This outcome will be assessed during both sessions, within 90 minutes post-treatment. | Planning and problem-solving abilities will be assessed using the Tower Test. Participants are asked to move disks to reach a specified end configuration in as few moves as possible. They can move only one disk at a time and cannot place a larger disk on top of a smaller disk. The primary outcome of interest is the Total Achievement Score across the tower problems, which reflects planning effectiveness. | ClinicalTrials.gov |
| Primary | Planning - Zoo Maps Test Total Achieved Score | This outcome will be assessed during both sessions, within 90 minutes post-treatment. | Planning and strategic thinking will be assessed using the Zoo Maps Test. Participants must plan a route through a provided zoo map while adhering to specified rules and efficiency constraints. For example, they may be instructed to start at the entrance, end at the picnic area, and use the designated paths only once. The primary outcome of interest is the total achieved score, representing accuracy when generating a self-directed route under the provided constraints. | ClinicalTrials.gov |
| Primary | Inhibitory Control - Stroop Test Interference Score | This outcome will be assessed during both sessions, within 90 minutes post-treatment. | Inhibitory control will be assessed using the Stroop test. Participants will be shown words whose letters are in a specific color (e.g., the word "blue" in red letters. They will be tasked with naming the color of the word, which may be incongruent with the word itself. The primary outcome of interest is the interference score, which reflects the difference in reaction times between the incongruent and congruent trials. | ClinicalTrials.gov |
| Primary | Inhibitory Control - Go/No-Go Accuracy | This outcome will be assessed during both sessions, within 90 minutes post-treatment. | Inhibitory control will be assessed using a computerized Go/No-Go task. Participants will respond as quickly and accurately as possible to designated "Go" stimuli and withhold their response when designated "No-Go" stimuli are presented. The primary outcome of interest is the number of accurate trials. Greater accuracy on the task will be indicative of greater inhibitory control. | ClinicalTrials.gov |
| Primary | Cognitive Flexibility - Intra-dimensional/Extra-dimensional Set-Shifting Task Errors | This outcome will be assessed during both sessions, within 90 minutes post-treatment. | Cognitive flexibility and attentional set-shifting will be assessed using the computerized Intra-Extra Dimensional Set-Shifting (IDED) task. Participants will select between paired visual stimuli based on learned rules and use feedback to determine the correct response as the relevant stimulus features and rules change across task stages. The primary outcome will be the number of errors committed during the extra-dimensional (ED) shift stage, in which participants must shift attention from a previously relevant stimulus dimension to a previously irrelevant dimension. Higher error scores indicate poorer cognitive flexibility. Other error types will be totaled, including simple discrimination errors, compound discrimination errors, reversal errors, and intra-dimensional (ID) errors. | ClinicalTrials.gov |
| Primary | Cognitive Flexibility - Intra-Dimesional/Extra Dimensional Set-Shifting Task Total Accuracy | This outcome will be assessed during both sessions, within 90 minutes post-treatment. | Cognitive flexibility and attentional set-shifting will be assessed using the computerized Intra-Extra Dimensional Set-Shifting (IDED) task. Participants will select between paired visual stimuli based on learned rules and use feedback to determine the correct response as the relevant stimulus features and rules change across task stages. Total accuracy will be measured as a representation of total task performance. | ClinicalTrials.gov |
| Primary | Cognitive Flexibility - Verbal Fluency, Category Switching Accuracy | This outcome will be assessed during both sessions, within 90 minutes post-treatment. | Cognitive flexibility (category switching) will be assessed using the verbal fluency category switching task. Participants will be given two categories (e.g., fruits and furniture) and be asked to generate words that belong to those categories, in alternating order, within a time limit of 60 seconds. The primary outcome of interest is category switching accuracy, which is the number of correct switches between the categories. | ClinicalTrials.gov |
| Primary | Cognitive Flexibility - Probabilistic Reversal Learning Task, Choice Accuracy | This outcome will be assessed during both sessions, within 90 minutes post-treatment. | Probabilistic reversal learning will be assessed using a computerized task in which participants select between two stimuli associated with different probabilities of receiving positive feedback. Participants will learn the more advantageous choice based on probabilistic feedback and must adjust their responses when the relative probabilities of the stimuli are reversed. The primary outcome of interest will be the proportion of trials on which participants select the stimulus associated with the higher probability of positive feedback. Higher advantageous-choice accuracy indicates more effective learning from probabilistic feedback. | ClinicalTrials.gov |
| Secondary | Post-Treatment (T1) Intoxication Rating | This outcome will be assessed during both sessions immediately after their vaping session. | Participants will be asked to rate how high they feel using a scale from 0 (not high at all) to 10 (extremely high) immediately after their vaping session. | ClinicalTrials.gov |
| Secondary | Post-Treatment (T1) Good Drug Effects Rating | This outcome will be assessed during both sessions immediately after their vaping session. | Participants will be asked to rate the level of good drug effects they are experiencing using a scale from 0 (none) to 10 (a lot) immediately after their vaping session. | ClinicalTrials.gov |
| Secondary | Post-Treatment (T1) Drug Effects Liking Rating | This outcome will be assessed during both sessions immediately after their vaping session. | Participants will be asked to rate how much they like the drug effects they are experiencing using a scale from 0 (not at all) to 10 (a lot) immediately after their vaping session. | ClinicalTrials.gov |
| Secondary | Post-Cogntiive Assessment (T2) Intoxication Rating | This outcome will be assessed during both sessions immediately after the stress challenge. | Participants will be asked to rate how high they feel using a scale from 0 (not high at all) to 10 (extremely high) immediately after the cognitive battery. | ClinicalTrials.gov |
| Secondary | Post-Cogntiive Assessment (T2) Good Drug Effects Rating | This outcome will be assessed during both sessions immediately after the stress challenge. | Participants will be asked to rate the level of good drug effects they are experiencing using a scale from 0 (none) to 10 (a lot) immediately after the nature video. | ClinicalTrials.gov |
| Secondary | Post-Cogntiive Assessment (T2) Drug Effects Liking Rating | This outcome will be assessed during both sessions immediately after the stress challenge. | Participants will be asked to rate how much they like the drug effects they are experiencing using a scale from 0 (not at all) to 10 (a lot) immediately after the nature video. | ClinicalTrials.gov |
| Secondary | Post-Nature Video (T3) Intoxication Rating | This outcome will be assessed during both sessions immediately after the nature video. | Participants will be asked to rate how high they feel using a scale from 0 (not high at all) to 10 (extremely high) immediately after the nature video. | ClinicalTrials.gov |
| Secondary | Post-Nature Video (T3) Good Drug Effects Rating | This outcome will be assessed during both sessions immediately after the nature video. | Participants will be asked to rate the level of good drug effects they are experiencing using a scale from 0 (none) to 10 (a lot) immediately after the nature video. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 10
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| 1-Back Task | Primary outcome | ConductCognition |
| 2-Back Task | Primary outcome | ConductCognition |
| Digit Span Test | Primary outcome | ConductCognition |
| Go/No-Go Task | Primary outcome | ConductCognition |
| Intra/Extra Dimensional Set Shift | Primary outcome | ConductCognition |
| Probabilistic Reversal Learning | Primary outcome | ConductCognition |
| Prospective Memory Task | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Verbal Fluency | Primary outcome | ConductCognition |
| Category Fluency | Other outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)